Faron Pharmaceuticals Oy · LSE:FARN
Faron Pharmaceuticals Oy — Investor Presentation (September 2025)
26 slides from Faron Pharmaceuticals Oy's investor presentation, September 2025
Slide 1: Non-confidential corporate deck
September 2025 Faron Pharmaceuticals Ltd Non-confidential corporate deck 1 FARON PHARMACEUTICALS LTD | 2025 NON-CONFIDENTIAL CORPORATE DECK
Slide 2: Corporate Disclaimer
Corporate Disclaimer The contents of this presentation have not been approved by an authorized person within the meaning of Section 21 of the Financial Services and Markets Act 2000 (as amended) ("FSMA"). Reliance on the contents of this presentation for the purpose of engaging in any investment act
Slide 3: Investment Highlights
Investment Highlights 1 High risk myelodysplastic syndrome (HR MDS) • One of the deadliest of all cancers, with no new treatments for 20 years and 40 000 new cases each year in the US and EU5 2 Lead asset bexmarilimab • A first-in-class anti-CLEVER-1, a master immunosuppressive receptor on myeloid c
Slide 4: Strengthened Management Team
Strengthened Management Team Dr. Juho Jalkanen Dr. Maija Hollmén MSc, MD, PhD PhD CEO and Founder Chief Scientific Officer Yrjö Wichmann Vesa Karvonen MSc LLM CFO General Counsel Dr. Petri Bono Ralph Hughes MD, PhD MSc, BSc Chief Medical Officer Chief Business Officer 4 FARON PHARMACEUTICALS LTD | 2
Slide 5: World Leading Scientific Advisory Board
World Leading Scientific Advisory Board Our Scientific Advisory Board is comprised of world leading hematologists and oncologists as well as industry professionals that have led significant R&D programs to successful commercialization of products. Toni Choueiri, MD, FASCO Naval G. Daver, MD Professo
Slide 6: Clever-1 is highly expressed in MDS and other hematological malignancies
Clever-1 is highly expressed in MDS and other hematological malignancies Clever-1 Clever-1 expression in Finnish biobank samples from patients with HaemOnc malignancies ▪ A scavenger receptor expressed by leukemic myeloid cells and immunosuppressive macrophage B-ALL BCL/TCL populations1 ▪ Involved i
Slide 7: Bexmarilimab – Mode of Action
Bexmarilimab – Mode of Action The first drug to tackle the core biology of HR MDS 1 Bexmarilimab deactivates the energy production of CLEVER-1 is an immunosuppressive receptor on macrophages immune cells, responsible for 3 the cancer cells, enabling existing therapies. (ie. AZA), eliminating infecte
Slide 8: Bexmarilimab – pipeline in a drug
Bexmarilimab – pipeline in a drug Bexmarilimab is primarily being developed for high-risk myelodysplastic syndrome (HR MDS) while also showing significant potential in multiple other indications and settings Phase of development Treatment Indication(s) Anticipate key milestones Preclinical Phase I P
Slide 9: BEXMAB Phase II Data
BEXMAB PHASE II DATA FARON PHARMACEUTICALS LTD | 2025 NON-CONFIDENTIAL CORPORATE DECK
Slide 10: BEXMAB Phase I/II Study Design
BEXMAB Phase I/II Study Design Study population Phase I dose escalation based on BOIN design, 1.0, 3.0 ▪ MDS: treatment naive intermediate, high/very high –risk and 6.0mg/kg bexmarilimab. ▪ MDS: failure to HMA (r/r) Phase II initiated in r/r (HMA-failed) HR MDS, at dose ▪ Relapsed/refractory (r/r) A
Slide 11: Unprecedented efficacy in last line HR MDS
Unprecedented efficacy in last line HR MDS June ’25 Data-cut for r/r MDS patients that have failed hypomethylating agent regimes n (%) Total Pt N = 32 IWG2006 CR 2 (6) PR 2 (6) Best change in bone marrow blast count by patient mCR 13 (41) HI 3 (9) SD 8 (25) Pending 4 (13) ORR (% of evaluable, n=32)
Slide 12: Last line MDS patients estimated mOS of 13.4 months
Last line MDS patients experienced an estimated mOS of 13.4 months compared to a historical 5–6 months r/r HR MDS (n=32) ▪ Median follow-up: 6.9 months; 95% CI 4.8-15.2 months ▪ mOS estimate: 13.4 months; 95% CI 4.8 months-not reached ▪ Median duration of treatment: 5.6 months; 95% CI 2.8- 11.8 ▪ Pr
Slide 13: Best-in-class efficacy also in frontline HR MDS
Best-in-class efficacy seen also in frontline HR MDS, in a severity-enriched population August’25 Data-Cut for frontline HR MDS n (%) Total Pt N=21 IWG 2006 CR 9 (43%) PR 1 (5%) mCR 5 (24%) HI 2 (10%) SD 2 (10%) No Response / 2 (10%) Progressive Disease ORR (% of evaluable, n=21) 81% ★ 35% of evalua
Slide 14: Why give another myelosuppressive drug to frail patients?
Why give another myelosuppressive and toxic drug to already frail and deeply cytopenic patients? Bex has an improved safety profile with potential for hematological recovery Bcl2: 43%-88% CD47: 36% Failed Assets TIM3: 62% Bcl2: 19%-71% CD47: 30%-79% Bexmarilimab Bcl2: 19%-65% Bcl2: 10%-65% CD47: 46%
Slide 15: Induction of hematopoiesis in bone marrow after Bex & Aza
Induction of hematopoiesis in the bone marrow of deeply cytopenic HR MDS patients after Bex & Aza After 3 cycles At entering trial of treatment Eo-Baso-Mast Precursor CXCL8hi Erythroid Precursor TGFB1hi MPP-MkEry/MEP PPARG+ LGALS2+ S100A12hi Increase in progenitor cells of erythocytes, leucocytes an
Slide 16: Positive BEXMAB end of Phase II meeting with the FDA
Positive BEXMAB end of Phase II meeting with the FDA 1. Clear Path to Registration FDA supports moving into a seamless Phase 2/3 trial design, enabling dose optimization (comparing 1 & 3 mg/kg to placebo) and registrational study start in frontline HR MDS in Q2 2026. 2. Frontline accelerated approva
Slide 17: Registrational study plan for HR MDS per FDA
Registrational study plan for HR MDS per FDA Seamless adaptive phase II/III with accelerated approval and re-sizing improves likelihood of success 2026 2027 2028 2029 2030 2031 H1 PHASE H2 II/III H1 H2 H1 H2 H1 PHASE H2 III & BLA H1 H2 H1 H2 Bexmarilimab 3mg/kg + azacitidine (n=40) FRONTLINE HR MDS
Slide 18: Major up-coming clinical milestones
Major up-coming clinical milestones On a mission to establish bexmarilimab as a cornerstone drug for cancer in indications where Clever-1 macrophages are a source of treatment resistance and cancer progression 2025 2026 2027 • ESMO25 BEXMAB oral presentation • Phase II/III BEXMAB-2 trial approval &
Slide 19: HR MDS Market Landscape
HR MDS MARKET LANDSCAPE FARON PHARMACEUTICALS LTD | 2025 NON-CONFIDENTIAL CORPORATE DECK
Slide 20: MDS is a fast-growing market with limited competition
MDS is a fast-growing market with limited competition HR MDS market growth1 MDS patient journey1 180-510k MDS Patients in the US & EU3 CAGR 26% $4,5 bn 2023–2028E 50% 50% Low-risk MDS High-risk MDS As a new, well tolerated effective 85% 15% treatment, bexmarilimab has the opportunity to 30-40% progr
Slide 21: Realistic price of $18-25k per month in HR MDS
Based on US payer insights, a price of $18-25k per month is realistic and achievable in HR MDS 21 FARON PHARMACEUTICALS LTD | 2025 NON-CONFIDENTIAL CORPORATE DECK
Slide 22: HR MDS significant untapped market with high up-take potential
HR MDS represents a significant untapped market with high up-take potential 18000 16000 14000 Number of Patients Treated EU5 12000 10000 USA 8000 6000 4000 2000 0 1. PharmaVentures market access report 22 FARON PHARMACEUTICALS LTD | 2025 NON-CONFIDENTIAL CORPORATE DECK
Slide 23: Bexmarilimab in Solid Tumors
BEXMARILIMAB IN SOLID TUMORS FARON PHARMACEUTICALS LTD | 2025 NON-CONFIDENTIAL CORPORATE DECK
Slide 24: Proof of single agent activity and tumor microenvironment modulation
Proof of single agent activity and modulation the tumor microenvironment, which leads to a survival benefit Phase 1/2 First-in-Human MATINS Trial Highlights • 216 patients treated across 10 different advanced and metastatic cancers • Targeting Clever-1 with bexmarilimab is well tolerated, RP2D 1mg/k
Slide 25: Bexmarilimab – a drug for cold (IFNg low) tumors
Bexmarilimab – a drug for cold (IFNg low) tumors As single agents bexmarilimab and anti-PD-1s benefit opposite melanoma populations Bex treated melanoma patients according Anti-PD1 treated melanoma patients according to to IFN gamma status3 IFN gamma status1,2 Pts achieving disease control Pts not a
Slide 26: Thank You
THANK YOU FARON PHARMACEUTICALS LTD | 2025 NON-CONFIDENTIAL CORPORATE DECK
Faron Pharmaceuticals — Investor Presentation (September 2025) on 6ix